Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections

Nosocomial Infections Clinical Trial

— CDSS  

Official title:

Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections: Integration of PCR Technology and Medical Informatics/Artificial Intelligence

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01338116
• Other study ID #: 6036
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: May 13, 2019

Study information

• Verified date: April 2024
• Source: Rabin Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Severe bacterial infections are associated with mortality of about 30%. Patients with moderate to severe bacterial infections given early and appropriate empirical antibiotic treatment are at a lesser risk for a fatal outcome, with odds ratios ranging from 1.6 to 6.9. However only about 2/3 of patients worldwide are given early and appropriate empirical antibiotic treatment. About 40% of patients treated with antibiotics are given superfluous treatment.

TREAT is a computerized decision support system for antibiotic treatment in inpatients with common bacterial infections. TREAT is based on a state of the art stochastic model of the domain (a causal probabilistic network) and uses a cost benefit model for antibiotic treatment, including costs assigned to future resistance. It was tested in a randomized controlled trial in 3 countries and shown to improve the percentage of appropriate empirical antibiotic treatment while at the same time reduce hospital stay and the use of broad-spectrum antibiotics. The main limitation of TREAT is inherent in the limited information available within hours of presentation.

A second attractive approach to improve antibiotic treatment is to use techniques that do not depend on cultures, and thus shorten the time to identification of the pathogen to a few hours only. The LightCycler® SeptiFast test from Roche performs in vitro nucleic acid amplification test for pathogens causing bloodstream infections.

The purpose of the clinical trial is to show that the combined system TREAT/PCR assays will improve the outcome of inpatients with moderate to severe bacterial infections, while at the same time reducing the use of broad-spectrum antibiotics, with no or little additional costs. A secondary objective will be to assess the sensitivity and specificity of whole blood PCR, using TREAT as the reference standard.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: May 13, 2019
• Est. primary completion date: May 13, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

The rationale of the study will be to address patients for whom antibiotic treatment is, or should be, considered. Thus we will include consecutive patients detected in medical departments according to the following criteria:

1. Patients from whom blood cultures were drawn or

2. All patients for whom antibiotic treatment (but not prophylaxis or intra-peritoneal, inhalation or local antibiotics therapy ) is started within the last 96 days or

3. Patients fulfilling the CDC diagnostic criteria for any infection (see appendix C) or

4. Patients with temperature =38.3 measured orally (or 38 axillary or 38.5 rectal) on a single measurement or =38 / < 36 on at least 2 consecutive measurements separated at least 1 hr apart and one of the next criteria:

(a) heart rate >90 beats/minute; (b) respiratory rate >20 breaths/minute or partial pressure of CO2 <32 mm Hg; and (c) white blood cell count >12,000/ L, <4000 L, or >10% immature (band) forms. or

5. Patients with shock compatible with septic shock. As defined as hypotension (arterial blood pressure <90 mmHg systolic, or 40 mmHg less than patient's normal blood pressure) for at least 1 h despite adequate fluid resuscitation; Or Need for vasopressors to maintain systolic blood pressure >90 mmHg or mean arterial pressure >70 mmHg and a suspected source of infection.

Exclusion Criteria:

1. HIV positive patients with opportunistic infection (suspected or proven)and / or AIDS defining illness in the last 6 months prior to data collection.

2. Children<18 years.

3. Suspected travel infections.

4. Suspected tuberculosis.

5. Pregnancy.

6. We will exclude patients not able to sign informed consent or not having a legal guardian willing to do so.

Related Conditions & MeSH terms

• Bacterial Infections
• Communicable Diseases
• Community-associated Infections
• Cross Infection
• Health-care Acquired Infections
• Infections
• Nosocomial Infections

Intervention

Other:
• antibiotic treatment of by TREAT/PCR
Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).

Locations

Country	Name	City	State
Israel	Rabin Medical Center, Beilinson Hospital	Petah Tikvah

Sponsors (1)

Lead Sponsor	Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical success defined as 30-day survival and clinical stability on day 4	patient alive at day 30; on day 4: no fever, no intra-tracheal tube, hemodynamic stable, no vasopressor support, empirical treatment appropriate (and thus not changed).	30 days
Secondary	Appropriate empirical antibiotic treatment	Appropriateness of the antibiotic treatment given during the first 48 hours, before identification of the causative pathogen and its antibiotic susceptibilities	48 hours
Secondary	Survival		30 days
Secondary	Hospital stay	Length of hospital stay	30 days
Secondary	Antibiotic miuse of broad spectrum antibiotics and total costs of antibiotic treatment Superfluous antibiotic treatment	Use of broad spectrum antibiotics and total costs of antibiotic treatment	30 days
Secondary	Costs	Costs incurred during hospital stay	30 days
Secondary	Adverse events	Allergy, nephrotoxicity, diarrhea, clostridium-difficile associated diarrhea and others	30 days